No Data
No Data
William Blair Maintains Neurogene(NGNE.US) With Buy Rating
William Blair analyst Sami Corwin maintains $Neurogene(NGNE.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 32.9% and a total average return of -6.1% over the past
Meridian Small Cap Growth Fund Trimmed Neurogene (NGNE) on Share Price Appreciation
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates.Quantum
Neurogene Down Over 22%, on Pace for Largest Percent Decrease Since June 2018 -- Data Talk
Neurogene Inc. ( NGNE ) is currently at $31.05, down $8.95 or 22.38% --Would be lowest close since May 13, 2024, when it closed at $30.64 --On pace for largest percent decrease since June 27, 2018,
Express News | Neurogene Shares Are Trading Lower. The Company Announced That the First Patient in Cohort 2 Received High-dose NGN-401 Gene Therapy in the Phase 1/2 Trial for Female Pediatric Patients With Rett Syndrome
Express News | Neurogene Announces First Patient Dosed in High-Dose Cohort of Ngn-401 Gene Therapy Clinical Trial for Rett Syndrome
No Data